Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMCQF) Cash & Current Investments (2016 - 2025)

Fresenius Medical Care AG has reported Cash & Current Investments over the past 17 years, most recently at $2.4 billion for Q4 2025.

  • Quarterly results put Cash & Current Investments at $2.4 billion for Q4 2025, up 38.07% from a year ago — trailing twelve months through Dec 2025 was $2.4 billion (up 38.07% YoY), and the annual figure for FY2025 was $2.4 billion, up 38.07%.
  • Cash & Current Investments for Q4 2025 was $2.4 billion at Fresenius Medical Care AG, up from $1.7 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for FMCQF hit a ceiling of $2.4 billion in Q4 2025 and a floor of $1.6 billion in Q4 2022.
  • Median Cash & Current Investments over the past 5 years was $1.7 billion (2024), compared with a mean of $1.8 billion.
  • Biggest five-year swings in Cash & Current Investments: fell 8.62% in 2022 and later soared 38.07% in 2025.
  • Fresenius Medical Care AG's Cash & Current Investments stood at $1.7 billion in 2021, then fell by 8.62% to $1.6 billion in 2022, then rose by 15.84% to $1.8 billion in 2023, then dropped by 4.1% to $1.7 billion in 2024, then soared by 38.07% to $2.4 billion in 2025.
  • The last three reported values for Cash & Current Investments were $2.4 billion (Q4 2025), $1.7 billion (Q4 2024), and $1.8 billion (Q4 2023) per Business Quant data.